cyrilzakka/clinical-trials huggingface dataset:
Effect of Virtual Reality Therapy on Dysphagia in Wallenberg Syndrome

The goal of this clinical trial is to learn about on dysphagia in wallenberg syndrome. The main questions it aims to answer are:

the efficacy of Virtual Reality Therapy in the rehabilitation of patients with dysphagia in Wallenberg syndrome.

Participants received conventional dysphagia treatment and Virtual Reality Therapy once a day for 14 days. Researchers compared the control group to see the effect and mechanism of Virtual Reality Therapy.

Virtual Reality technology has revolutionized various fields, and its application in rehabilitation medicine is particularly noteworthy. Virtual Reality provides immersive environments that simulate real-life situations, making it an invaluable tool in the rehabilitation process.

The goal of this clinical trial is to learn about on dysphagia in wallenberg syndrome. The main questions it aims to answer are:

the efficacy of Virtual Reality Therapy in the rehabilitation of patients with dysphagia in Wallenberg syndrome.

Participants received conventional dysphagia treatment and Virtual Reality Therapy once a day for 14 days. Researchers compared the control group to see the effect and mechanism of Virtual Reality Therapy.

Eligibility Criteria:
Inclusion Criteria:

* age ranged from 18-85 years and right-handed;
* first onset, vital signs stable and conscious;
* the dysphagia confirmed by videofluoroscopic swallowing study;
* no cognitive impairment, the mini-mental state examination score: \>17 for those with an illiterate education, \>20 for those with an elementary education, and \>24 for those with a secondary education and above;
* cranial integrity without craniotomy and/or craniectomy;
* patient and/or his/her relative agrees and signs written informed consent.

Exclusion Criteria:

* combined ischemic foci at other sites;
* presence of organic swallowing dysfunction or pre-existing dysphagia due to Parkinson's disease, dementia, and others;
* severe cardiac, pulmonary, hepatic, and renal insufficiency and vital organ failure;
* infected or broken skin on the head;
* poorly controlled epilepsy;
* poor patient compliance.
Serological Identification of Celiac Disease in Kids

The investigators aim to examine the feasibility of incorporating serological celiac disease (CD) screening into general pediatric outpatient clinics in Sweden and through structured monitoring examine the effects of diagnosing and treating screening-detected CD.

Screening will be tailored to general pediatric outpatient clinics in the Gothenburg metropolitan area with the goal to screen 1000 children over four months. Screening for CD will be carried out by measuring tissue transglutaminase autoantibodies (TGA) in blood. Children who are persistently TGA positive will be enrolled into a 6-12-month follow-up protocol responsible for diagnosing CD, installation of gluten-free diet and to assess their short-term impact upon the child's wellbeing. Other components to assess include (I) the feasibility to incorporate CD screening into busy pediatric practices; (II) parental/child interest in, and satisfaction with, participating in a CD screening program and (III) identifying key considerations for a possible scaled-up, broad-based, CD screening.


Eligibility Criteria:
Inclusion Criteria:

* Aged 2-17 years old
* Patient at pediatric outpatient clinics in Gothenburg metro area
* Parental and adolescent consent to screening

Exclusion Criteria for serological screening:

* Established celiac disease diagnosis
* Type 1 diabetes
Non-invasive Evaluation of Upper and Lower Body Function With Showmotion

It is very important to understand joint and body kinematics and muscles activity in clinical settings, which is relevant to identify issues related to the spine, the upper and lower limbs due to injury.

In this study, the investigators will use an innovative platform, Showmotion to establish baseline of shoulder, hip, knee and spine kinematics and muscles activity from 60 healthy volunteers.

Upper and lower body functional evaluation is challenging and relevant to identify the issues related to injury. Current technique still stays at visual observation.

Showmotion™ (NCS Lab, Carpi, Italy) is an innovative platform that provides a comprehensive analysis to monitor motion patterns of the whole body using WISE sensors, proprietary wireless inertial and magnetic units (MIMU) developed by NCS Lab (Italy).

Using the data acquired from MIMU and validated protocols for upper and lower limbs, Showmotion is able to measure, objectify and store three dimensional kinematic variables highlighting underlying information and allowing an in-depth analysis of the movement in real time.

Compared to the classic motion analysis performed with cameras in special research laboratories, the Showmotion™ technology allows the user to analyze the movements of the subjects in any place, quickly, and without the need to a long process of data analysis.

Eligibility Criteria:
Inclusion Criteria:

* Healthy people (without musculoskeletal pathologies of the joint of interest)
* Age \> 18, \<65
* Volunteers given written informed consent
* Ability to understand and execute instructions at all stages of the procedure

Exclusion Criteria:

* Age \> 65, \< 18
* Active infections
* Surgery at joint of interest
* BMI (Body Mass Index) \>30 kg/m2
* Pregnancy
CyberKnife for Prostate Cancer Patients Aged 70 y or More

Robotic Stereotactic Radiation treatment of prostatic adenocarcinoma of the elderly.

Inclusion criteria : T1-T3b, MRI pelvic nodes negative, M0, any Gleason Score, PSA (Prostate Specific Antigen) \<30ng/ml.

Dose : 36.25 Gy in 5 fractions, in 10 days, considering CAPRA Scores≤5 AND 37.5 Gy in 5 fractions, in 10 days, considering CAPRA Scores\>5.

Primary objective : acute and late toxicity evaluation at 36 months. Secondary objectives : PSA and MRI response.

Robotic Stereotactic Radiation treatment of prostatic adenocarcinoma of the elderly.

Rationale : Half of the prostatic adenocarcinoma are diagnosed in the elderly but until now curative treatments were not proven to increase overall survival rates. Therefore, very short, comfortable and safe treatments have to be designed to increase the pelvic control of the disease. Moreover, the alpha/beta ratio of the disease ≤3Gray is in favour of using hypofractionation schemes.

Primary objective : acute and late toxicity evaluation at 36 months. Secondary objectives : PSA and MRI response and quality of life evaluation.

Inclusion criteria : T1-T3b, MRI pelvic nodes negative, M0, any Gleason Score, PSA\<30ng/ml.

Dose : 36.25 Gray in 5 fractions, in 10 days, considering CAPRA Score≤5 AND 37.5 Gray in 5 fractions, in 10 days, considering CAPRA Scores\>5.

Doses to the Organs At Risk (OAR) : Rectum wall : V36.25\<2%, V27\<20%, V23\<30%, V20\<35%. Bladder wall : V36.25\<2%, V27\<20%, V20\<35%. Considering specifically the prescription of 37.5 Gray, the rectum and bladder wall: V37.5\<2%. Anytime, hot spots of 105 % of the prescription dose must avoid the urethra.

Evaluation criteria : CTCAEV4 (Common Toxicity Criteria for Adverse Events, version4), PSA, multiparametric MRI, IPSS (International Prostate Score Symptom) and IIEF5 (International Index of Erectile Function).

Methodolgy : this is a three step prospective, observational study of 20 patients each step. Before moving to the next step, the severe acute or late toxicity at a median follow-up of 1 year must remain below 5% each.

Eligibility Criteria:
Inclusion Criteria:

* T1-T3b,
* MRI pelvic nodes negative,
* M0,
* any Gleason Score,
* PSA\<30ng/ml,
* WHO (World Health Organisation) score\<2, IPSS≤15,
* maximal urinary flow rate ≥15ml/s,
* mean urinary flow rate ≥5ml/s,
* multiparametric prostatic and pelvis MRI

Exclusion Criteria:

* Prostatic volume \> 100cc,
* TURP (transurethral prostatectomy) \<3 y,
* any recurrent prostatitis within the last 3 years,
* collagenose diseases,
* ulcero-haemorrhagic rectocolitis or
* crohn diseases
Pain and Music Therapy in Patients Suffering Arteritis

It is estimated that 800,000 people in France suffer from peripheral artery disease (PAD), of whom 1-2% present the most severe form critical limb ischaemia (CLI). In this situation, the patient frequently presents painful non-healing ulcers and focal gangrene. Wound care is generally associated with increasing pain. Pain relief may be challenging in spite of major analgesics.

Several studies in this country and elsewhere assessed the usefulness of music for chronic or acute pain relief during care. However, no data are published regarding the interest of music therapy for pain relief during local care in PAD patients.


Eligibility Criteria:
Inclusion Criteria:

* Men and women, aged at least 18 years, affiliated to the health insurance scheme.
* Patients affected by arteritis of stage 5 or 6 at Limoges University Hospital in department cardiovascular Surgery.
* Patients requiring a daily repair of bandage, not exceeding fifteen minutes and provoking a pain
* Initial pain equal to three during local care in the digital scale.
* Having given their enlightened consent writes

Exclusion Criteria:

* Bypass and / or angioplasty lower than one week
* Diabetic neuropathy
* Patient who is going to undergo a surgery of amputation
* Patients affected by demented pathologies or by confusion
* Pregnant or breast-feeding women or without effective contraception
* Patients being the object of a saving of justice
Usefulness of BiClamp Forceps for Liver Resection: A Randomized Clinical Trial

The purpose of this study is to compare short-term and long-term efficacy of BiClamp forceps hepatectomy and clamp-crushing technique for parenchymal transection during elective hepatic resection.

Background: Blood loss and the need for blood transfusions during the liver transection have shown to be correlated with higher morbidity and mortality rates and with worsen prognosis. Various devices of liver parenchymal transection have been developed with a view to reducing the intraoperative blood loss. However, to the present there is no randomized controlled trial evaluating the technique of BiClamp forceps during the liver transection. The goal of the present study was to evaluate the safety and effectiveness of BiClamp forceps transection in comparison to the clamp crushing technique in patients offered liver resection.

Intervention: One hundred patients with hepatobiliary disease need undergo hepatectomy at Anhui medical university were selected and divided into BiClamp forceps hepatectomy group and clamp-crushing hepatectomy group, each group contains 50 cases.

Results:

1. Clinical data include: blood loss during liver transection, total blood loss, blood transfusion, hospital stay, morbidity, mortality, biliary leakage, postoperative liver function, liver transection time, operation time, resection margins, need for portal trial clamping.
2. Statistical method: groups t-test, univariate/multivariate analysis, logistic regression analysis, mixed linear regression and Cox survival analysis were used.

Eligibility Criteria:
Inclusion Criteria:

* Both male and female, aged 18 or older
* Patients scheduled to undergo hepatic resection for some benign or malignant hepatobiliary disease
* Child-Pugh class A or B liver function
* BiClamp forceps hepatectomy and clamp-crushing feasible based on preoperative imaging
* No tumor invasion the main vein, hepatic artery and vein and major inferior vena cava
* No extrahepatic metastasis
* Voluntary participation in the study, and informed consent.

Exclusion Criteria:

* Age \<18 years or\> 65 years , pregnant or lactating women
* Preoperative liver function evaluation: Child-Pugh C grade
* Laparoscopic hepatectomy
* Extrahepatic metastasis
* Tumor invasion the main vein, hepatic artery and vein and major inferior vena cava
* The patient refused to sign the informed consent form
Pleuropulmonary Echography Versus Standard Chest X-ray in the Post-operative Follow-up of Pleuropulmonary Surgery

In postoperative pleuro-pulmonary surgery, the monitoring of the appearance of complications is guided, depending on the centres, by the systematic daily performance or, in the event of a call point, by chest x-ray at the patient's bed until the drains are ablative.

This repeated performance of radiographs results in irradiation of patients but also of medical staff and a significant cost.

In the thoracic study, ultrasound imaging is a fast, cost-effective, non-irradiating solution that can be performed at the patient's bedside. It could guide the performance of chest x-ray, limit their number, with increased clinical relevance.


Eligibility Criteria:
Inclusion Criteria:

* Patient with a higher age to 18 and undergoing pleuro-pulmonary surgery
* Hospitalized patient at Martinique University Hospital
* Patient receiving social security
* Patient giving his free and informed consent orally

Exclusion Criteria:

* Patient minor
* Woman who is pregnant and breast feeding
* Patient no giving his free and informed consent orally
Determining Normal Range for Free Light Chains in Serum Among Twins

The objective of this study is to recruit healthy adult identical and fraternal twins for the collection of one teaspoon of blood to be sent to the Clinical Lab at San Francisco General Hospital. The serum will be tested to determine the reference range for free light chains.

Serum free light chains are used to assist in the diagnosis of multiple myeloma. The test measures kappa (K) and lambda (L) chains, and the calculation of the ratio of kappa to lambda (K/L). Previous studies have shown that the K/L ratio does not change over time (1 year). The hypothesis of this study is that healthy twins will have a K/L ratio that are close to each other in value, suggesting that this ratio is genetically linked.

Eligibility Criteria:
Inclusion Criteria:

* Healthy subjects 18-80 years.
* Must be an identical or fraternal twin (both must be recruited)

Exclusion Criteria:

* Symptoms suggestive of multiple myeloma (e.g., renal insufficiency, anemia, bone pain) -
NEPH-ROSIS (NEPHrology in CirRhOSIS) Pilot Trial: A Trial to Treat Acute Kidney Injury Among Hospitalized Cirrhosis Patients

The goal of this pilot, randomized, single-blind clinical trial is to estimate the effect size of a high and low mean arterial pressure (MAP)-target algorithm among cirrhosis patients hospitalized with acute kidney injury. The main aims to answer are: • Does an algorithm that has low (\<80 mmHg) and high (≥80) MAP-targets lead to significant differences in mean arterial pressure? • Are there any serious adverse events (e.g., ischemia) in a high blood pressure algorithm as compared to a low blood pressure algorithm? • Are there any differences in the incidence of AKI reversal in the high v. low MAP-target groups? Participants will be: 1) Randomized to a clinical algorithm that will either target a low (\<80 mmHg) or high (≥80 mmHg) MAP. 2) Depending on their group, investigators will titrate commonly used medications to a specific MAP target. Researchers will compare the high and low MAP-target groups to see if these algorithms lead to significant changes in MAP, if they have any impact on AKI reversal, and if there are any adverse events in the high MAP-target group.


Eligibility Criteria:
Inclusion Criteria:

* Hospitalized patients with decompensated cirrhosis, defined as a Child-Pugh Score ≥ 7
* Acute Kidney Injury: a ≥50% increase in sCr from an outpatient baseline sCr measured 7 to 365 days prior to admission

Exclusion Criteria:

1. Patients without a baseline (7 - 365 days prior to AKI development) sCr measurement;
2. Patients who are already on kidney replacement therapy (KRT) at the time of enrollment;
3. Patients with an oxygen requirement greater than 6L via nasal cannula;
4. Patients with a serum creatinine level exceeding 5 mg/dL.
Longitudinal Analysis of Respiratory and Intestinal Microbiome in Cystic Fibrosis

Respiratory und intestinal microbiome will bei analyzed during a period of 6 months. In a retrospective analysis it will be looked for correlations between microbiome and cf therapy (e.g. inhaled and systemic antibiotics, cftr modifiers, proton pump Inhibitors, enzymes, nutritional habits), clinical status and self reported outcome.

DNA will be isolated from sputum, throat swabs and stool samples and used for the generation of microbial profiles. Both bacterial and fungal profiles will be analyzed by next generation sequencing.

Clinical outcome parameters (lung function test, weight, calprotectin, elastase, blood parameters, self reported outcome) will be recorded and analyzed along with medication.

Eligibility Criteria:
Inclusion Criteria:

* subject has confirmed diagnosis of cystic fibrosis (sweat chloride \>60mmol/l and/or 2 mutations in the cftr gene known to cause cystic fibrosis)
* subject is able to perform informed consent

Exclusion Criteria:

* inability to give informed consent
* antibiotic therapy in the last 4 weeks prior to study start (exception: long term azithromycin therapy, long term antistaphylococcal therapy, long term inhaled antibiotics)
Clinical Characteristics and Outcomes Among STEMI Patients with Cardiogenic Shock At Abu Dhabi City

A retrospective study on the clinical characteristics and treatment outcomes of patients admitted with ST-elevation Myocardial Infarction (STEMI) complicated with cardiogenic shock (CS) during admission or CS development during their hospital stay for two tertiary hospitals in Abu Dhabi, UAE, from 2020-2024.

Cardiovascular disease (CVD) accounts for 40% of mortality in the UAE, which is higher than the global average. Long-term trends, incidence studies, and best practice guidance on Cardiogenic Shock (CS) with ST-elevation Myocardial infarction (STEMI) in the United Arab Emirates (UAE) and the Gulf Cooperation Council (GCC) are limited.

Through this retrospective study, investigators aim to identify treatment modalities and trends, hospitalization events, and patient demographics and comorbidities which lead to participant recovery or mortality in Sheikh Khalifa Medical City (SKMC) and Sheikh Shakhbout Medical City (SSMC) tertiary hospitals for patients admitted with STEMI and CS or developed CS after hospitalization with STEMI during January 2020-January 2024.\[200-400 participants\]. Data will be collected from eligible patients' electronic medical records (EMR).

Eligibility Criteria:
Inclusion Criteria:

* Age more than 18.
* STEMI complicated by cardiogenic shock.
* Were hospitalized or treated at SSMC or SKMC for STEMI complicated by cardiogenic shock.
* Patient admitted between January 2019 to March 2024.

Exclusion Criteria:

* Age less than 18.
* Shock patient not related to Myocardial infarction.
* NSTEMI-related cardiogenic shock.
* Patients who were not treated at SSMC or SKMC for the STEMI complicated by cardiogenic shock.
* Patient not admitted between January 2019 to March 2024.
Influence of Anaesthesia Type on Multiple Sclerosis Relapse

The influence of anesthesia on the course of multiple sclerosis is poorly investigated and the literature is limited.

The aim of this study is to investigate multiple sclerosis relapse after different types of anesthesia.

The influence of anesthesia on the course of multiple sclerosis is poorly investigated and the literature is limited. A possible relapse after neuraxial anesthesia, it is believed to be associated with local anesthetic's toxicity and concentration.

The aim of this study is to investigate multiple sclerosis relapse after different types of anesthesia.

Eligibility Criteria:
Inclusion Criteria:

* multiple sclerosis
* surgical procedure under general anaesthesia
* surgical procedure under neuraxial anaesthesia

Exclusion Criteria:

* patients (medical records) with incomplete data
Optimal Management of Pain in Hospitalized Patients - Opioid Tolerant Populations.

Pain is a symptom that drives hospital admissions, and pain management is required by most patients during their hospital stay. Further, the use of medications such as opioids can lead to upward-spiraling doses, especially among chronic pain patients whose resource utilization rates are high. Many initiatives aim to reduce the costs of these "high-resource utilizing" patients. One exciting aspect of improving the management of pain is that this may help prevent patients from ever becoming high-cost in the first place. The purpose of this study is to examine the impacts of an early and sustained intervention pathway, in comparison to the current standard of care, for the treatment of pain in opioid tolerant patients. It is hypothesized that patients randomized to the intervention pathway, in comparison to the control, will lead to decreased costs of care, a reduction in opioid usage within 3 and 6 months, and decrease in hospital readmission rates.


Eligibility Criteria:
Inclusion Criteria:

* Adult patients (18 years and older)
* Known opioid tolerant (as determined per FDA criteria)
* Agree to sign the informed consent and HIPAA forms

Exclusion Criteria:

* Patients under the age of 18 years
* No known opioid tolerance
* Do not agree to sign the informed consent and HIPAA forms